Ευρωπαϊκή Ένωση -
Ισλανδικά -
EMA (European Medicines Agency)
lunsumio
roche registration gmbh - mosunetuzumab - eitilæxli, follicular - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
Ισλανδία -
Ισλανδικά -
LYFJASTOFNUN (Icelandic Medicines Agency)
abstral tungurótartafla 800 míkróg
kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 800 míkróg
Ισλανδία -
Ισλανδικά -
LYFJASTOFNUN (Icelandic Medicines Agency)
abstral tungurótartafla 600 míkróg
kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 600 míkróg
Ισλανδία -
Ισλανδικά -
LYFJASTOFNUN (Icelandic Medicines Agency)
abstral tungurótartafla 400 míkróg
kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 400 míkróg
Ισλανδία -
Ισλανδικά -
LYFJASTOFNUN (Icelandic Medicines Agency)
abstral tungurótartafla 300 míkróg
kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 300 míkróg
Ισλανδία -
Ισλανδικά -
LYFJASTOFNUN (Icelandic Medicines Agency)
abstral tungurótartafla 200 míkróg
kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 200 míkróg
Ισλανδία -
Ισλανδικά -
LYFJASTOFNUN (Icelandic Medicines Agency)
abstral tungurótartafla 100 míkróg
kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 100 míkróg
Ισλανδία -
Ισλανδικά -
LYFJASTOFNUN (Icelandic Medicines Agency)
sandimmun innrennslisþykkni, lausn 50 mg/ml
novartis healthcare a/s - ciclosporinum inn - innrennslisþykkni, lausn - 50 mg/ml
Ισλανδία -
Ισλανδικά -
LYFJASTOFNUN (Icelandic Medicines Agency)
creon magasýruþolið hart hylki 35.000
viatris aps - pancreatinum - magasýruþolið hart hylki - 35.000
Ισλανδία -
Ισλανδικά -
LYFJASTOFNUN (Icelandic Medicines Agency)
bendamustine accord stofn fyrir innrennslisþykkni, lausn 2,5 mg/ml
accord healthcare b.v. - bendamustinum hýdróklóríð - stofn fyrir innrennslisþykkni, lausn - 2,5 mg/ml